Dalton Pharma Services has successfully completed a comprehensive drug development program for the CELADEN trial, which included Celgosivir process development, cGMP API and capsule manufacturing in support of Duke-NUS’s clinical research program.   The Phase Ib trial to evaluate Celgosivir as a treatment for Dengue has opened for enrolment following the successful completion of API development and manufacture of the final dosage form by Dalton Pharma Services.   “We are pleased to have reached ...